La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Arch Biopartners Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Richard Muruve

Directeur général

CA$150.0k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	15yrs
Propriété du PDG	15.0%
Durée moyenne d'occupation des postes de direction	12.9yrs
Durée moyenne du mandat des membres du conseil d'administration	14.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Richard Muruve a-t-elle évolué par rapport aux bénéfices de Arch Biopartners?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	n/a	n/a	-CA$2m
Sep 30 2023	CA$150k	CA$150k	-CA$3m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	n/a	n/a	-CA$3m
Sep 30 2022	CA$113k	CA$113k	-CA$1m
Jun 30 2022	n/a	n/a	-CA$257k
Mar 31 2022	n/a	n/a	-CA$423k
Dec 31 2021	n/a	n/a	CA$308k
Sep 30 2021	CA$100k	CA$100k	-CA$1m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$383k	CA$100k	-CA$5m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	n/a	n/a	-CA$2m
Sep 30 2019	CA$100k	CA$100k	-CA$2m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	n/a	n/a	-CA$3m
Sep 30 2018	CA$100k	CA$100k	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$2m
Dec 31 2017	n/a	n/a	-CA$2m
Sep 30 2017	CA$100k	CA$100k	-CA$2m

Rémunération vs marché: La rémunération totale de Richard ($USD 110.43K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 679.79K ).

Rémunération et revenus: La rémunération de Richard a augmenté alors que l'entreprise n'est pas rentable.

PDG

Richard Muruve (53 yo)

15yrs

Titularisation

CA$150,000

Compensation

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and President since May 12, 2010. Mr. Muruve served as Acting Chief Financial...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Richard Muruve	Co-Founder	15yrs	CA$150.00k	15.03% CA$ 10.4m
Daniel Muruve	Co-Founder	12.9yrs	CA$289.00k	3.17% CA$ 2.2m
Andrew Bishop	CFO & Director	no data	CA$289.00k	1.21% CA$ 834.6k
Justin MacDonald	Co-Founder & Principal Scientist	no data	pas de données	pas de données
Paul Beck	Co-Founder & Principal Scientist	no data	pas de données	pas de données
Aaron Benson	Director of Communications	1.1yrs	pas de données	pas de données

12.9yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de ACHF.F est chevronnée et expérimentée (ancienneté moyenne 12.9 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Richard Muruve	Co-Founder	19yrs	CA$150.00k	15.03% CA$ 10.4m
Daniel Muruve	Co-Founder	no data	CA$289.00k	3.17% CA$ 2.2m
Andrew Bishop	CFO & Director	14.3yrs	CA$289.00k	1.21% CA$ 834.6k
Claude Allary	Independent Director	10.3yrs	CA$289.00k	0.32% CA$ 221.5k
Richard Rossman	Independent Director	14.3yrs	pas de données	3.31% CA$ 2.3m
Robert Hodges	Member of Scientific Advisory Board	no data	pas de données	pas de données
Hindrik Mulder	Member of Scientific Advisory Board	no data	pas de données	pas de données

14.3yrs

Durée moyenne de l'emploi

63.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration ACHF.F sont chevronnés et expérimentés (durée moyenne d'administration 14.3 ans).

Arch Biopartners Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Recent updates

Arch Biopartners Inc. Announces its Cilastatin Drug Candidate to Participate in Pontiac Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.6 million in funding

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen